Clinical Trial Update: A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial comparing dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or Stage III mismatch repair proficient/microsate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Dostarlimab (dostarlimab)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Colon | Phase 2 | Status: RECRUITING